BeiGene to present new data on hematology portfolio and pipeline

BeiGene is presenting new data across a range of assets and blood cancers at the upcoming 65th American Society of Hematology Annual Meeting and Exposition December 9-12 in San Diego. BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations. Brukinsa continues to show sustained PFS benefit versus ibrutinib in the global Phase 3 ALPINE trial of patients with R/R CLL/SLL with this longer follow up. Durable PFS was observed across major subgroups. Overall safety and tolerability profile was consistent with previous ALPINE analyses, including persistently lower rates of cardiovascular events reported with BRUKINSA. Based on these results, BRUKINSA continues to be a more efficacious and better-tolerated treatment than ibrutinib for patients with R/R CLL/SLL. Data from Waldenstrom Macroglobulinemia patients who switched to receive BRUKINSA on a long-term extension study demonstrate generally improved safety and deepening of responses with the switch to BRUKINSA. In an ongoing Phase 2 study, data suggest that for patients intolerant of acalabrutinib, switching to BRUKINSA leads to better tolerance while maintaining or deepening response. Patients with treatment-naive CLL/SLL were treated with sonrotoclax in combination with BRUKINSA. The combination was observed to be well tolerated; no cases of tumor lysis syndrome were observed. There was a 100% response rate. Sonrotoclax has also been well tolerated with high response rates as monotherapy in a Phase 1 study in patients with R/R marginal zone lymphoma. Sonrotoclax was also evaluated in combination with dexamethasone in patients with R/R multiple myeloma. The combination is safe and efficacious, with the majority of patients across all dose levels achieving clinical response, including deep responses.